Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer's Analyst Day: And Now, For Its Next Trick

Executive Summary

Pfizer was vague in describing to analysts just how it would reduce costs by $4 billion per year by 2008. The FDA's announcement that it had asked Pfizer to remove the Cox-2 inhibitor Bextra from the market just days later complicates matters for the pharmaceutical giant. In any case, those hoping for a significant headcount reduction among Pfizer sales reps were surely disappointed.

Related Content

Big Pharma's Year of Big Layoffs
Best Laid Plans: Pfizer's Torcetrapib Tanks
Pfizer's Change Management: Unfamiliar Faces
Pfizer Sets New Biotech M&A Record
Biomarkers: Shaking Up--and Protecting--the World's Biggest Drug Market
Insomnia: Pharma Wakes Up to the Next Huge CNS Market
Pfizer Trims Altana From Pipeline
DTC Advertising Under Pressure
Message Problems: One Key Lesson from the Cox-2 Advisory Panel
The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts